A Trial Asks When Enough Radiation Is Enough

GE HealthCare and Mayo Clinic test whether imaging, not a fixed schedule, should guide prostate cancer therapy.

14 Jul 2026

Most cancer treatments still follow a preset number of cycles, regardless of how a patient's tumor actually responds. GE HealthCare and Mayo Clinic want to test a different premise. Their new collaboration, the Molecular Imaging Biomarker Based End of Therapy Trial, or MI-BET, will examine whether imaging and biomarker data can guide adaptive treatment for men with advanced prostate cancer.

The study pairs GE HealthCare's StarGuide SPECT CT system with MIM Software's MIM LesionID Pro to track tumor response throughout therapy, folding imaging data together with clinical outcomes and blood based biomarkers. Work will be based at Mayo Clinic's campus in Rochester, Minnesota, the first American site to test GE HealthCare's next generation StarGuide GX technology.

Sergio Calvo, global general manager of theranostics at GE HealthCare, said making theranostics genuinely adaptive requires strong clinical evidence and a sharper understanding of individual patient response. Geoffrey Johnson, who chairs the Radiopharmaceutical Trial Team at Mayo Clinic Comprehensive Cancer Center, called such studies a chance to rethink how and when cancer is treated.

The project builds on a 2023 research alliance between the two organizations and reflects a wider shift toward dosing frameworks that respond to a patient's own biology rather than a standardized protocol. Should it succeed, the approach could reshape how radioligand therapy is administered more broadly, carrying sector wide interest in personalized dosimetry into a real world clinical setting.